Furthermore, this study established a new mechanistic framework for the antitumour effect of EA in NSCLC, identifying the ROS-AMPK-mTOR-SCD1 signalling pathway as a key target, making EA a promising therapeutic candidate for NSCLC. Here, SCD is linked to non-small cell lung carcinoma.